Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $268

Benzinga · 3d ago
Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $267 to $268.